Michael Tocco, PhD

Long-term Efficacy of Lurasidone in Antipsychotic-Naive vs. Antipsychotic-Exposed Adolescents with Schizophrenia: Post-hoc Analysis of a Two Year, Open-label Study

Background: The aim of this post-hoc analysis was to evaluate the long-term efficacy of lurasidone in antipsychotic-naïve adolescents with schizophrenia.

Robert Goldman , PhD;

Christoph U. Correll , MD;

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Jay Hsu , PhD;

10/08/2020

Effect of Lurasidone on Cognition in Adolescents With Schizophrenia: Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the short and long-term effects of lurasidone on cognitive performance in adolescents with schizophrenia.

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

Philip Harvey , PhD;

Josephine Cucchiaro , PhD;

Michael Tocco , PhD;

03/01/2019

Long-term Efficacy of Lurasidone in Pediatric Bipolar Depression: Post-hoc Analysis of Response, Remission and Recovery

Background: The aim of this analysis was to evaluate the long-term efficacy of lurasidone in achieving response and remission in children and adolescents with bipolar depression.

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Manpreet Singh , MD, MS;

Edward Schweizer , MD;

10/08/2020

Efficacy and Safety of Lurasidone in a Younger Population With Bipolar Depression: Pooled Post-hoc Analysis of Two Placebo-controlled Studies

Abstract: Introduction: The aim of this analysis was to evaluate the efficacy and safety of lurasidone in bipolar depression in youth and young adult patients (10-30 years old). Methods:...

Michael Tocco , PhD;

01/19/2023

Effect of Lurasidone on Manic Symptoms and Treatment-Emergent Mania in Children and Adolescents with Bipolar Depression

Background: The aim of these analyses was to assess the effect of lurasidone on manic symptoms and treatment-emergent (TE) mania in pediatric patients with bipolar depression.

Michael Tocco , PhD;

Robert Goldman , PhD;

Andrei Pikalov , MD, PhD;

Courtney Zeni , PhD;

10/08/2020

Long-term safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies

Abstract: Introduction: The aim of this pooled analysis was to evaluate the long-term safety and effectiveness of lurasidone in the treatment of schizophrenia in adolescents (13-17 years)...

Michael Tocco , PhD;

01/19/2023

Long-term Efficacy of Lurasidone in Antipsychotic-naïve vs. Antipsychotic-exposed Adolescents With Schizophrenia: Post-hoc Analysis of a Two Year, Open-label Study

Background: Few studies have prospectively evaluated short- or long-term antipsychotic efficacy in treatment-naïve (vs. previously treated) first-episode schizophrenia. The aim of this po...

Robert Goldman , PhD;

Christoph U. Correll , MD;

Michael Tocco , PhD;

Jay Hsu , PhD;

11/22/2019

Safety and Effectiveness of Lurasidone in Children and Adolescents With Bipolar Depression: Results From a 2-Year Open-label Extension Study

Objective: The aim of the current study was to evaluate the long-term safety and effectiveness of lurasidone in pediatric bipolar depression. Method: Patients 10-17 years with bipolar I ...

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Melissa DelBello , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

11/22/2019

Lurasidone and Metabolic Syndrome: Results From Short- and Long-Term Clinical Studies in Patients With Bipolar Depression

Background: The elevated prevalence of metabolic syndrome (MetS) in patients with depression has been associated with increased mortality rates. The aim of this post-hoc analysis was to a...

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Yongcai Mao , PhD;

John Newcomer , MD;

11/22/2019

Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: Results of a 12-week Open-label Extension Study

Objective: To evaluate the efficacy and tolerability of longer-term treatment with lurasidone in patients with major depressive disorder (MDD) with mixed features.

Antony Loebel , MD;

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Stephen Stahl , MD;

Yongcai Mao , PhD;

03/01/2019